Unicycive Therapeutics (UNCY) Operating Margin (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly Operating Margin came in at 622.52% in Q1 2023, down 6.59% on a QoQ basis from 584.02% in Q3 2022.
Unicycive Therapeutics (UNCY) Operating Margin (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of Operating Margin data on file, last reported at 622.52% in Q1 2023.
- Quarterly Operating Margin changed N/A year-over-year to 622.52% in Q1 2023, while the trailing twelve-month figure through Dec 2023 was 3077.78% (changed N/A YoY) and the FY2023 annual result came in at 3077.63%, down 117942.0% from the prior year.
- Operating Margin declined to 622.52% in Q1 2023, from 584.02% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 584.02% in Q3 2022 to a low of 622.52% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 19.75% |
| 10 | Unicycive Therapeutics | 149.66 Mn | 149.66 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -622.52% |
| Sep 30, 2022 | -584.02% |